Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Forecasted Growth Rate and Market Size of the Insulin biosimilars Market?

The market size of insulin biosimilars has witnessed a quick expansion in the recent years. Predicted to swell from $3.04 billion in 2024 to $3.5 billion in 2025, its compound annual growth rate (CAGR) is 15.1%. The historical growth in this sector can be linked to a rise in diabetes incidences, an upsurge in healthcare expenditures, broader accessibility to diabetes care, competitive market scenarios, pricing tensions, and favourable regulatory endorsements and approval protocols.

In the coming years, significant expansion is predicted for the insulin biosimilars market, with projections estimating it will reach $6.04 billion in 2029, growing at a compound annual growth rate (CAGR) of 14.6%. This anticipated growth over the forecast period is due to factors such as the global diabetes epidemic, the growth of emerging markets, expanding access, policies favoring biosimilar adoption, patient preference for cost-effective treatment, and collaboration and partnerships within the biopharmaceutical industry. Moving forward, the market may witness trends like the diversification of insulin product offerings, increased global market penetration, the application of technology in insulin delivery, regulatory backing for the development of biosimilars, and a more patient-focused approach in product development.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10661&type=smp

Which Factor Is Shaping The Future Of The Insulin biosimilars Market?

The insulin biosimilars market is expected to surge due to the growing prevalence of diabetes, a group of chronic metabolic conditions characterized by extended periods with high blood sugar levels. Biosimilars contribute significantly towards the management of diabetes by offering a replacement for insulin therapy. This escalation in diabetes consequently enhances the demand for the insulin biosimilars market. For example, the National Center for Biotechnology Information, a US government institution that provides biomedical and genomic information, reported in July 2023 that the prevalence of diabetes was 10.5% in 2021 and is forecasted to increase to 11.3% by 2030, climbing still to 12.2% by 2040. Accordingly, this rise in instances of diabetes is fueling the growth of the insulin biosimilar market.

What Is The Segment-Wise Breakdown Of The Insulin biosimilars Market?

The insulin biosimilars market covered in this report is segmented –

1) By Biosimilars Type: Rapid Acting biosimilars, Long Acting biosimilars, Premixed Acting biosimilars

2) By Disease Indication Type: Type I Diabetes, Type II Diabetes

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By End User: Hospitals, Ambulatory Surgical Centers, Other End Users

Subsegments:

1) By Rapid Acting Biosimilars: Insulin Aspart Biosimilars, Insulin Lispro Biosimilars, Insulin Glulisine Biosimilars

2) By Long Acting Biosimilars: Insulin Glargine Biosimilars, Insulin Detemir Biosimilars, Insulin Degludec Biosimilars

3) By Premixed Acting Biosimilars: Insulin Aspart Protamine Biosimilars, Insulin Lispro Protamine Biosimilars, Biphasic Insulin Biosimilars

Which Trends Are Redefining The Future Landscape Of The Insulin biosimilars Industry?

Major players in the insulin biosimilars market are focusing on the production of interchangeable insulin. This development is pivotal in providing better patient accessibility, driving down healthcare costs, and ensuring uniform results in diabetes treatment. The role of interchangeable insulin is integral in the insulin biosimilars market for it deepens patient’s access to cost-effective remedies and encourages consistent therapy. For instance, Eli Lilly, a pharmaceutical company based in the U.S., launched an insulin glargine biosimilar, Rezvoglar (insulin glargine-aglr) in April 2023 with the aim to improve glucose control in both adult and pediatric patients with type 1 diabetes and adults suffering from type 2 diabetes. Thanks to its interchangeable designation, this product can be swapped for other insulin glargine prescriptions without needing a doctor’s consent, thus expanding patient access. The introduction of Rezvoglar makes it the second interchangeable insulin biosimilar in the U.S. market, fueling competition and making treatments more affordable in the insulin biosimilars market.

Which Companies Hold The Largest Market Share In The Insulin biosimilars Sector?

Major companies operating in the insulin biosimilars market include Eli Lilly and Company, Boehringer Ingelheim GmbH, Merck & Co Inc., Pfizer Inc., Biocon Ltd., Mylan N.V., Wockhardt Limited, NOVO Nordisk A/S, Sanofi S.A, Fresenius Kabi AG, Sandoz International GmbH, Novartis International AG, Aurobindo Pharma Ltd., Intas Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Ltd., Samsungbioepis Co. Ltd., Teva Pharmaceutical Industries Ltd., Stada Arzneimittel AG, Celltrion Inc., Fujifilm Kyowa Kirin Biologics Co. Ltd., Green Cross Corporation, Lupin Limited, Torrent Pharmaceuticals Ltd., Zydus Lifescience Ltd.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/insulin-biosimilars-global-market-report

How Does Regional Performance Compare Across The Insulin biosimilars Industry?

North America was the largest region in the insulin biosimilars market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global insulin biosimilars market report during the forecast period. The regions covered in the insulin biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10661&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model